Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to
placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in
patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed
6 to 18 months of treatment with vitamin K antagonist (VKA).